Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Abstract Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then block the activation of downstream sign...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-10-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-020-00977-0 |
id |
doaj-5adb93bde37e447fb7b9fd11a0d65568 |
---|---|
record_format |
Article |
spelling |
doaj-5adb93bde37e447fb7b9fd11a0d655682020-11-25T04:04:10ZengBMCJournal of Hematology & Oncology1756-87222020-10-0113112310.1186/s13045-020-00977-0Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)Liling Huang0Shiyu Jiang1Yuankai Shi2Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted DrugsDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted DrugsDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted DrugsAbstract Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then block the activation of downstream signaling pathways. Over the past 20 years, multiple robust and well-tolerated TKIs with single or multiple targets including EGFR, ALK, ROS1, HER2, NTRK, VEGFR, RET, MET, MEK, FGFR, PDGFR, and KIT have been developed, contributing to the realization of precision cancer medicine based on individual patient’s genetic alteration features. TKIs have dramatically improved patients’ survival and quality of life, and shifted treatment paradigm of various solid tumors. In this article, we summarized the developing history of TKIs for treatment of solid tumors, aiming to provide up-to-date evidence for clinical decision-making and insight for future studies.http://link.springer.com/article/10.1186/s13045-020-00977-0Tyrosine kinase inhibitorsSolid tumorsTargeted therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Liling Huang Shiyu Jiang Yuankai Shi |
spellingShingle |
Liling Huang Shiyu Jiang Yuankai Shi Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) Journal of Hematology & Oncology Tyrosine kinase inhibitors Solid tumors Targeted therapy |
author_facet |
Liling Huang Shiyu Jiang Yuankai Shi |
author_sort |
Liling Huang |
title |
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) |
title_short |
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) |
title_full |
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) |
title_fullStr |
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) |
title_full_unstemmed |
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) |
title_sort |
tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) |
publisher |
BMC |
series |
Journal of Hematology & Oncology |
issn |
1756-8722 |
publishDate |
2020-10-01 |
description |
Abstract Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then block the activation of downstream signaling pathways. Over the past 20 years, multiple robust and well-tolerated TKIs with single or multiple targets including EGFR, ALK, ROS1, HER2, NTRK, VEGFR, RET, MET, MEK, FGFR, PDGFR, and KIT have been developed, contributing to the realization of precision cancer medicine based on individual patient’s genetic alteration features. TKIs have dramatically improved patients’ survival and quality of life, and shifted treatment paradigm of various solid tumors. In this article, we summarized the developing history of TKIs for treatment of solid tumors, aiming to provide up-to-date evidence for clinical decision-making and insight for future studies. |
topic |
Tyrosine kinase inhibitors Solid tumors Targeted therapy |
url |
http://link.springer.com/article/10.1186/s13045-020-00977-0 |
work_keys_str_mv |
AT lilinghuang tyrosinekinaseinhibitorsforsolidtumorsinthepast20years20012020 AT shiyujiang tyrosinekinaseinhibitorsforsolidtumorsinthepast20years20012020 AT yuankaishi tyrosinekinaseinhibitorsforsolidtumorsinthepast20years20012020 |
_version_ |
1724437378126315520 |